Results for
""Antithrombins""[mesh_terms]

Dabigatran must be used carefully: literature review and recommendations for management of adverse events.

Shan Lin, Yan Wang, Lei Zhang, Wei Guan

Drug design, development and therapy 2020;13():1527-1533

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.

Gillian M Keating, Hannah A Blair

Drugs 2017;77(3):331-344

Warfarin versus dabigatran: comparing the old with the new.

Mary Elizabeth Abraham, Todd R Marcy

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 2012;27(2):121-4

Peptidomimetic thrombin inhibitors.

Danijel Kikelj

Pathophysiology of haemostasis and thrombosis 2005;33(5-6):487-91

Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update.

Ke Xu, Noel C Chan, John W Eikelboom

Expert opinion on drug metabolism & toxicology 2021;17(9):1091-1102

A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation.

Richard C Becker, James W Wisler

Critical pathways in cardiology 2012;11(2):55-61

Affinity capillary electrophoresis in binding study of antithrombin to heparin from different sources.

Roberto Gotti, Bruna Parma, Franco Spelta, Lino Liverani

Talanta 2013;105():366-71

A metabolomics discrimination-based strategy for screening the antithrombin active markers of perilla seeds: A natural oil crop.

Xue Meng, Suyi Liu, Xingyue Jin, Rui Wang, Kunze Du, Jin Li, Xiumei Gao, Yanxu Chang

Food chemistry 2023;432():137183

Exploring antithrombin: insights into its physiological features, clinical implications and analytical techniques.

Muhammad Saboor, Hassan A Hamali, Abdullah A Mobarki, Aymen M Madkhali, Gasim Dboie

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2024;35(2):43-48

Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.

Timothy S Leung, Ernest H Law

Drug design, development and therapy 2016;9():3557-69

Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use.

Vivek Iyer, Harsimran S Singh, James A Reiffel

Journal of cardiovascular pharmacology and therapeutics 2013;17(3):237-47

A pharmacologic overview of current and emerging anticoagulants.

Edith A Nutescu, Nancy L Shapiro, Aimee Chevalier, Alpesh N Amin

Cleveland Clinic journal of medicine 2005;72 Suppl 1():S2-6

idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote.

Prescrire international 2019;25(176):260-263

Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation.

Diana R Mack, Jenny J Kim

The Annals of pharmacotherapy 2012;46(7-8):1105-10

New oral anticoagulants in elderly patients with atrial fibrillation.

Prakash C Deedwania

The American journal of medicine 2013;126(4):289-96